Coronary/Structural Heart

ATCC and Tissue Dynamics Announce a Strategic Collaboration to Bring a Transformative Heart Organoid Model to Market

MANASSAS, Va. & TEL AVIV, Israel–(BUSINESS WIRE)–ATCC, the world’s premier biological materials management and standards organization, and Tissue Dynamics, a disruptive pharma-tech company integrating advanced artificial intelligence tools with bionic human organoids, today announced a partnership to develop workflow friendly cardiac organoids-based kits for improved cardiac safety testing in drug development. […]

Aria CV Announces First Patient Successfully Implanted with Second-Generation Pulmonary Hypertension System

SAINT PAUL, Minn.–(BUSINESS WIRE)–Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the first patient was implanted with the Gen 2 Aria CV Pulmonary Hypertension System as part of the ASPIRE PH clinical trial at Ascension St. Vincent Cardiovascular Research Institute in Indianapolis, Indiana. The implant […]

Manuscript Discussing the Benefit of SeaStar Medical’s Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients DENVER, Feb. 27, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital […]

Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

DENVER–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care to aid in the diagnosis of heart disease, announced that its recently U.S. Food and Drug Administration (FDA)-cleared Cleerly ISCHEMIA software device applied to a non-invasive coronary CT angiogram (CCTA) can be billed using the new Category I CPT® code 75580. The American […]

PrepMD Partners with MediaSphere and Esteemed Cardiac Experts for Groundbreaking Virtual Device Clinic Leadership Summit

BRAINTREE, Mass., Feb. 21, 2024 /PRNewswire/ — PrepMD, as the exclusive sponsor, is thrilled to announce its partnership with MediaSphere and distinguished cardiac professionals, including Beth Davenport and Sallie Gustafson, to present the largest-ever virtual accredited Cardiac Device…

Saghmos Therapeutics Announces Appointment of FDA Veteran Stephen Grant, MD, as Chief Regulatory Officer

GREENWICH, Conn.–(BUSINESS WIRE)–Saghmos Therapeutics, Inc. (Saghmos), a privately held biopharmaceutical company, announced the appointment of Stephen Grant, MD, as Chief Regulatory Officer. Dr. Grant was the former Deputy Director, Division of Cardiology and Nephrology at the FDA. During his more than 20-year career at the FDA, he was responsible for […]

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total Artificial Heart

GOLD COAST, Australia & HUNTINGTON BEACH, Calif.–(BUSINESS WIRE)–BiVACOR®, a clinical-stage medical device company, today announced $13 million (USD) awarded from the Australian Government’s Medical Research Future Fund (MRFF) grant through the Artificial Heart Frontiers Program (AHFP) to support BiVACOR’s Total Artificial Heart program and future product enhancements. Led by Monash […]

Reprieve Cardiovascular Emerges from Stealth Mode after $42 Million Series A Financing to Bring Intelligent Fluid Management to Heart Failure Patients

MILFORD, Mass.–(BUSINESS WIRE)–Reprieve Cardiovascular, Inc., a development stage company focused on pioneering an intelligent automated diuretic and fluid management approach for acute decompensated heart failure (ADHF) treatment, today announced it has raised a total of $42 million in series A financing. The total round was co-led by Lightstone Ventures and […]

Cleerly® Announces CERTAIN Multicenter Clinical Trial Results

Study Results Demonstrate the Prominent Effects of Cleerly’s Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease DENVER – February 8, 2024 — Cleerly, the company working to create a new standard of care to aid in the diagnosis of heart disease, announced continued strong scientific evidence supporting […]

Study Results: MD Revolution and Cardiac Solutions Achieve 50% Reduction in 30-Day Cardiovascular Readmissions Using RevUp Remote Care Management

SAN DIEGO–(BUSINESS WIRE)–MD Revolution, the leader in remote care management solutions for health systems and multi-specialty clinics, announced today that its partner, Cardiac Solutions achieved a 50% reduction in hospital cardiovascular readmission rates by using RevUp Remote Patient Monitoring and Chronic Care Management as part of their program. “Our goal […]